Preparation, anticholinesterase activity, and docking study of new 2-butenediamide and oxalamide derivatives

References

• Lambert J, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet 2009;41:1094–9
   PubMed Web of Science ®Google Scholar
• Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nat Genet 2011;43:436–41
   PubMed Web of Science ®Google Scholar
• Piazzi L, Rampa A, Bisi A, et al. Extensive SAR and computational studies of 3-{4-[(benzylmethylamino)methyl]phenyl}-6,7-dimethoxy-2H-2-chromenone (AP2238) derivatives. J Med Chem 2003;46:2279–82
   PubMed Web of Science ®Google Scholar
• Seshadri S, Fitzpatrick AL, Ikram MA, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. J Am Med Assoc 2010;303:1832–40
   PubMed Web of Science ®Google Scholar
• Singh M, Kaur M, Kukreja H, et al. Acetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to neuroprotection. Eur J Med Chem 2013;70:165–88
   PubMed Web of Science ®Google Scholar
• Massoud F, Léger G. Pharmacological treatment of Alzheimer disease. Can J Psychiatry 2011;56:579–88
   PubMed Web of Science ®Google Scholar
• Winslow B, Onysko M, Stob C, Hazlewood K. Treatment of Alzheimer disease. Am Fam Physician 2011;83:1403–12
   PubMed Web of Science ®Google Scholar
• Akasofu S, Kimura M, Kosasa I, et al. Study of neuroprotection of donepezil, a therapy for Alzheimer’s disease. Chem Biol Interact 2008;175:222–6
   PubMed Web of Science ®Google Scholar
• Dumas JA, Newhouse PA. The cholinergic hypothesis of cognitive aging revisited again: cholinergic functional compensation. Pharmacol Biochem Behav 2011;99:254–61
   PubMed Web of Science ®Google Scholar
• Tai HC, Serrano-Pozo A, Hashimoto T, et al. The synaptic accumulation of hyperphosphorylated tauoligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol 2012;181:1426–35
   PubMed Web of Science ®Google Scholar
• Skrzypek A, Matysiak J, Niewiadomy A, et al. Synthesis and biological evaluation of 1,3,4-thiadiazole analogues as novel AChE and BuChE inhibitors. Eur J Med Chem 2013;62:311–19
   PubMed Web of Science ®Google Scholar
• Darvesh S, Hopkins DA, Geula C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 2003;4:131–8
   PubMed Web of Science ®Google Scholar
• Greig NH, Utsuki T, Ingram DK, et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc Natl Acad Sci USA 2005;102:17213–18
   PubMed Web of Science ®Google Scholar
• Bullock R, Lane R. Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase. Curr Alzheimer Res 2007;4:277–93
   PubMed Web of Science ®Google Scholar
• Jhee SS, Shiovitz T, Hartman RD, et al. Centrally acting antiemetics mitigate nausea and vomiting in patients with Alzheimer’s disease who receive rivastigmine. Clin Neuropharmacol 2002;25:122–3
   PubMed Web of Science ®Google Scholar
• Kamal MA, Klein P, Luo W, et al. Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine. Neurochem Res 2008;33:745–53
   PubMed Web of Science ®Google Scholar
• Mesulam MM, Guillozet A, Show P, et al. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 2002;110:627–39
   PubMed Web of Science ®Google Scholar
• Basiri A, Murugaiyaha V, Osman H, et al. An expedient, ionic liquid mediated multi-component synthesis of novel piperidone grafted cholinesterase enzymes inhibitors and their molecular modeling study. Eur J Med Chem 2013;67:221–9
   PubMed Web of Science ®Google Scholar
• Khoobi M, Alipour M, Moradi A, et al. Design, synthesis, docking study and biological evaluation of some novel tetrahydrochromeno [3′,4′:5,6]pyrano[2,3-b]quinolin-6(7H)-one derivatives against acetyl- and butyrylcholinesterase. Eur J Med Chem 2013;68:291–300
   PubMed Web of Science ®Google Scholar
• Budimir A. Metal ions, Alzheimer’s disease and chelation therapy. Acta Pharm 2011;61:1–14
   PubMed Web of Science ®Google Scholar
• Liu G, Huang W, Moir RD, et al. Metal exposure and Alzheimer’s pathogenesis. J Struct Biol 2006;155:45–51
   PubMed Web of Science ®Google Scholar
• Zatta P, Drago D, Bolognin S, Sensi SL. Alzheimer’s disease, metal ions andmetal homeostatic therapy. Trends Pharmacol Sci 2009;30:346–55
   PubMed Web of Science ®Google Scholar
• Loef M, Walach H. Copper and iron in Alzheimer’s disease: a review and its dietary implications. Br J Nutr 2012;107:7–19
   PubMed Web of Science ®Google Scholar
• Dong J, Atwood CS, Anderson VE, et al. Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry 2003;42:2768–73
   PubMed Web of Science ®Google Scholar
• Opazo C, Huang X, Cherny RA, et al. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem 2002;277:40302–8
   PubMed Web of Science ®Google Scholar
• Yan H, Yao PF, Chen SB, et al. Synthesis and evaluation of 7,8-dehydrorutaecarpine derivatives as potential multifunctional agents for the treatment of Alzheimer’s disease. Eur J Med Chem 2013;63:299–312
   PubMed Web of Science ®Google Scholar
• Ellman GL, Courtney D, Andies V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88–95
   PubMed Web of Science ®Google Scholar
• Musileka K, Komloova M, Holas O, et al. Preparation and in vitro screening of symmetrical bis-isoquinolinium cholinesterase inhibitors bearing various connecting linkage – implications for early Myasthenia gravis treatment. Eur J Med Chem 2011;46:811–18
   PubMed Web of Science ®Google Scholar
• Huang W, Lv D, Yu H, et al. Dual-target-directed 1,3-diphenylurea derivatives: BACE 1 inhibitor and metal chelator against Alzheimer’s disease. Bioorg Med Chem 2010;18:5610–15
   PubMed Web of Science ®Google Scholar
• Joseph R, Ramanujam B, Acharya A, et al. Experimental and computational studies of selective recognition of Hg2+ by amide linked lower rim 1,3-dibenzimidazole derivative of calix[4]arene: species characterization in solution and that in the isolated complex, including the delineation of the nanostructures. J Org Chem 2008;73:5745–58
   PubMed Web of Science ®Google Scholar
• Yerdelen KO, Gul HI. Synthesis and anticholinesterase activity of fumaramide derivatives. Med Chem Res 2013;22:4920–9
   Web of Science ®Google Scholar